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Insulin sparing effect of hydroxychloroquine 
in uncontrolled diabetes mellitus
AbstrAct
Hydroxychloroquine (HcQ) has a favorable glycemic 
effect that provides a rationale for its use in diabetes 
mellitus. Decreased insulin degradation and increased 
insulin sensitivity is suggested to contribute to the 
reduction in serum glucose levels. Herein, we present 
a case on the beneficial impact of HCQ on glycemic 
control in diabetes mellitus. 
A 69-year old female suffering from type 2 diabetes 
mellitus presented to the clinic for routine follow up. 
For management of diabetes she was taking glime-
piride 4mg once daily, combination of metformin and 
sitagliptin (1000/50 mg) twice daily and 94 units of 
insulin/day. baseline fasting plasma glucose (FPG) and 
postprandial plasma glucose (PPG) levels were 183 and 
222 mg/dL respectively and glycosylated hemoglobin A 
(HbA1c) level was 8.4%. to achieve glycemic control 
HcQ 400 mg once daily was initiated as an add on 
antidiabetic drug. 
HbA1c level decreased to 6.9% at four months and to 
6.8% at eight months after HcQ was utilized. FPG level 
decreased to 110 mg/dL at six months and to 114 mg/dL 
at eight months. PPG level decreased to 178 mg/dL 
at six months and 130 mg/dL at eight months. thus 
the FPG level decreased by 69 mg/dL and PPG level 
decreased by 92 mg/dL respectively from baseline. 
Acknowledging the progressive positive response to 
antidiabetic agents, the insulin dose was decreased to 
56 units/day at four months, 42 units/day at six months 
and 28 units/day at eight months. 
the case highlights the potential ability of HcQ to lower 
HbA1c and decrease insulin requirement in uncontrolled 
diabetic patients. (clin Diabetol 2016; 5, 4: 138–140)
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Introduction
Approximately 50% of Indian respondents had 
poor diabetes control in a multi-country study con-
ducted in Asia [1]. Uncontrolled hyperglycemia has 
deleterious effects on the human vascular tree and are 
the major source of morbidity and mortality in type 2 
diabetes mellitus (T2DM). One or more oral antidiabetic 
treatment options are required by most patients such as 
metformin along with sulfonylurea, thiazolidinedione 
and DPP-4 inhibitor. Many patients eventually require 
insulin therapy. In patients with suboptimal blood 
glucose control, especially those requiring increasing 
insulin doses, adjunctive use of novel antidiabetics 
agents may be helpful in improving glucose control 
and reducing the amount of insulin needed. 
Hydroxychloroquine:  
novel antidiabetic drug
Hydroxychloroquine (HCQ) has a unique mode of 
action which is different from other antidiabetic drugs. 
It causes inhibition of insulin degradation in cells thus 
enhancing the metabolic effects of the hormone and 
has also shown to improve insulin sensitivity in non-
diabetic obese individuals [2].
An epidemiological study has reported 77% reduc-
tion in development of diabetes in rheumatoid arthritis 
patients with HCQ use for more than four years com-
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pared to never users. It is known to reduce cardiovas-
cular risk in rheumatoid arthritis and lupus patients [3]. 
The release of various inflammatory mediators are be-
lieved to play a critical role in insulin resistance, b-cell 
dysfunction, dyslipidemia as well as atherosclerosis. The 
anti-inflammatory effects exerted by HCQ are notewor-
thy since these pathogenic mechanisms are implicated 
in the progression to T2DM [2]. It is approved in India 
as an adjunct to improve glycemic control of patients 
on metformin and sulfonylurea combination in T2DM.
Glycemic control with HCQ
Hydroxychloroquine has shown a positive effect 
on glycemic control in patients with diabetes and may 
provide a means for better disease management. Qua-
traro A et al. [4] noted that there was more decrease 
in glycemic profile (–11.7 mmol/L vs –0.9 mmol/L) and 
HbA1c level (–3.3% vs –0.3%) in patients treated with 
insulin and HCQ 400 mg as compared to patients 
treated with insulin and placebo. The daily insulin dose 
of patients in the HCQ group also had to be reduced 
by an average of 30% [4]. Pareek et al. [2] showed that 
HCQ 400 mg has comparable hypoglycemic effects to 
those of pioglitazone 15 mg as a third-line treatment 
in T2DM patients inadequately controlled on a com-
bination of glimepiride or gliclazide and metformin. 
Hence consideration may be given for addition of HCQ 
in uncontrolled diabetics. 
Case presentation
A 69-year old female suffering from type 2 diabetes 
mellitus since nine years and one month presented 
for routine health check up. Her past medical history 
includes hypertension with ischemic heart disease. On 
examination blood pressure (BP) was 100/70 mm Hg, 
weight was 90.7 kg and body mass index (BMI) was 
33.7 kg/m2. No abnormal findings were detected on 
systemic examination. For management of blood glu-
cose levels she was taking glimepiride 4mg once daily, 
combination of metformin and sitagliptin (1000/50 mg) 
twice daily and biphasic isophane insulin suspension 
consisting of 25% dissolved insulin and 75% crystalline 
protamine insulin 44 units in morning and 50 units 
in evening. She was also taking aspirin 150 mg, ator-
vastatin 10 mg, telmisartan 40 mg and multivitamin 
multimineral supplements. 
Laboratory investigations revealed that the fasting 
plasma glucose (FPG) and postprandial plasma glucose 
(PPG) levels were 183 and 222 mg/dL respectively and 
HbA1c level was 8.4%. As the plasma glucose levels were 
uncontrolled and target HbA1c was not achieved she was 
prescribed HCQ 400 mg once daily as an add on drug 
to the current antidiabetics and was asked to follow-up 
after 3 months. Baseline ophthalmological examination 
was conducted before initiation of HCQ and was normal.
Outcome and follow-up
Subsequent follow-up visit at four months revealed 
that the HbA1c level had decreased to 6.9% and random 
plasma glucose (RPG) level was 167.3 mg/dL. Blood 
pressure was 140/90 mm Hg at this visit. As the target 
HbA1c was achieved and plasma glucose level was under 
control the insulin dose was decreased to 26 units in 
morning and 30 units in evening. Other medications 
were continued unchanged. 
FPG and PPG levels at six months follow-up visit 
decreased to 110 and 178 mg/dL respectively. Blood 
pressure was 140/70 mm Hg at this visit. Acknowl-
edging the positive response to antidiabetic agents, 
the insulin dose was further decreased to 22 units in 
morning and 20 units in evening. There was a further 
decrease in HbA1c level at eight months to 6.8% ac-
companied by a decrease in FPG and PPG to 114 mg/dL 
and 130 mg/dL respectively (Table 1). RPG has also de-
creased to 86.6 mg/dL. At this visit BP was 143/72 mm Hg, 
weight was 89.4 kg and BMI was 33.2 kg/m2. The 
insulin dose was decreased to 12 units in the morning 
and 16 units in the evening. All the therapies were well 
tolerated and she did not report any fresh complaints 
at this visit.
Discussion
Lifestyle and environmental changes over the last cen-
tury have resulted in a dramatic increase in the incidence 
of diabetes in India. Prevention of diabetes and control 
of its micro- and macrovascular complications will require 
an integrated approach to cause significant reduction in 
the huge premature morbidity and mortality. 
table 1. Fasting plasma glucose (FPG) and postprandial plasma glucose (PPG) levels at baseline, 6 and 8 months of HcQ 
therapy
Plasma glucose 
levels
baseline 6 months 8 months Decrease from baseline
FPG [mg/dL] 183 110 114 –69
PPG [mg/dL] 222 178 130 –92
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Hydroxychloroquine works through a novel mecha-
nism and may therefore be a useful adjunctive therapy 
for patients with T2DM [2]. In the current case its use as 
an add on antidiabetic drugs resulted in achievement 
of target HbA1c level along with the control of plasma 
glucose levels. HbA1c level decreased by 1.6% and FPG 
and PPG levels decreased by 69 mg/dL and 92 mg/dL 
respectively after HCQ was added to the treatment 
regimen. Due to glycemic control the daily insulin dose 
could be reduced by 66 units. Thus there was a 70% 
reduction in daily insulin dose requirement. 
A recently conducted retrospective cohort study 
showed that use of HCQ was associated with 72% car-
diovascular (CV) disease risk reduction in RA patients. 
The hazard ratio was 0.28 (p = 0.002) for CV disease 
events and 0.30 (p = 0.004) for composite coronary 
artery disease, stroke, and transient ischemic attack 
for HCQ users versus nonusers respectively [5]. The 
cardiovascular risk may also be diminished by HCQ due 
to beneficial lipid lowering, antiplatelet and antithrom-
botic effects [6].
Hydroxychloroquine is generally considered to be 
a very safe medication. The major safety concern with 
long-term HCQ use is retinopathy, the incidence of 
which according to the American Academy of Ophthal-
mology can be minimized by keeping the daily dose 
< 6.5 mg/kg/day [7].
Conclusion
Hydroxychloroquine should be considered as a ther-
apeutic option in the refractory diabetic patients, since 
glycemic control is achieved through inhibition of insulin 
degradation and improvement of insulin sensitivity. This 
case report illustrates the need for clinicians to have a 
heightened awareness about the antidiabetic effect of 
HCQ. Anti-inflammatory action, cholesterol and triglyc-
eride lowering effect, antiplatelet and antithrombotic 
actions of HCQ may lower the cardiovascular risk. But 
such an overwhelming response of HCQ on metabolic 
parameters cannot be expected in every individual. 
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Figure 1. Daily insulin dose requirement (Y axis) by months of HCQ therapy (X axis)
